CN102430146A - Negative pressure treatment wound surface patch containing metal ion antibacterial agent and preparation method thereof - Google Patents
Negative pressure treatment wound surface patch containing metal ion antibacterial agent and preparation method thereof Download PDFInfo
- Publication number
- CN102430146A CN102430146A CN201110393626XA CN201110393626A CN102430146A CN 102430146 A CN102430146 A CN 102430146A CN 201110393626X A CN201110393626X A CN 201110393626XA CN 201110393626 A CN201110393626 A CN 201110393626A CN 102430146 A CN102430146 A CN 102430146A
- Authority
- CN
- China
- Prior art keywords
- woven fabrics
- metal ion
- negative pressure
- antibacterial
- pressure treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910021645 metal ion Inorganic materials 0.000 title claims abstract description 42
- 238000011282 treatment Methods 0.000 title claims abstract description 36
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 46
- 229920001661 Chitosan Polymers 0.000 claims description 79
- 239000004745 nonwoven fabric Substances 0.000 claims description 74
- 239000011505 plaster Substances 0.000 claims description 33
- 229920002635 polyurethane Polymers 0.000 claims description 20
- 239000004814 polyurethane Substances 0.000 claims description 20
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 17
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 17
- 229910001431 copper ion Inorganic materials 0.000 claims description 17
- 238000006116 polymerization reaction Methods 0.000 claims description 17
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 15
- 238000010521 absorption reaction Methods 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 15
- 230000006196 deacetylation Effects 0.000 claims description 14
- 238000003381 deacetylation reaction Methods 0.000 claims description 14
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 14
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 14
- 229910052751 metal Inorganic materials 0.000 claims description 12
- 239000002184 metal Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 63
- 230000000694 effects Effects 0.000 abstract description 14
- 230000003115 biocidal effect Effects 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 9
- 230000035876 healing Effects 0.000 abstract description 8
- 206010056340 Diabetic ulcer Diseases 0.000 abstract description 6
- 230000001684 chronic effect Effects 0.000 abstract description 5
- 230000017423 tissue regeneration Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000007789 sealing Methods 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 57
- 239000012530 fluid Substances 0.000 description 12
- 239000011701 zinc Substances 0.000 description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 11
- 150000004676 glycans Chemical class 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 229920001282 polysaccharide Polymers 0.000 description 11
- 239000005017 polysaccharide Substances 0.000 description 11
- 229910052725 zinc Inorganic materials 0.000 description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 10
- 229910052802 copper Inorganic materials 0.000 description 10
- 239000010949 copper Substances 0.000 description 10
- 102000003792 Metallothionein Human genes 0.000 description 9
- 108090000157 Metallothionein Proteins 0.000 description 9
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 9
- 229910052709 silver Inorganic materials 0.000 description 9
- 239000004332 silver Substances 0.000 description 9
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005253 cladding Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- JDKLPDJLXHXHNV-MFVUMRCOSA-N (3s,6s,9r,12s,15s,23s)-15-[[(2s)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1h-imidazol-5-ylmethyl)-3-(1h-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxamide Chemical compound C([C@@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCNC(=O)C[C@@H](C(N[C@@H](CC=2NC=NC=2)C(=O)N1)=O)NC(=O)[C@@H](NC(C)=O)CCCC)C(N)=O)C1=CC=CC=C1 JDKLPDJLXHXHNV-MFVUMRCOSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- UAHFGYDRQSXQEB-PWPYQVNISA-N 4-nle-α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 UAHFGYDRQSXQEB-PWPYQVNISA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710201354 Metallothionein A Proteins 0.000 description 1
- 101710201349 Metallothionein B Proteins 0.000 description 1
- 101710094503 Metallothionein-1 Proteins 0.000 description 1
- 102100031347 Metallothionein-2 Human genes 0.000 description 1
- 101710094505 Metallothionein-2 Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000027380 protein glycosylation in Golgi Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The invention relates to a wound surface patch containing a metal ion antibacterial agent and used for sealing a negative pressure treatment wound surface and having antibacterial and tissue repair promoting functions and a preparation method thereof. The invention provides a negative pressure treatment wound surface patch containing a metal ion antibacterial agent and a preparation method thereof, which ensure effective implementation of negative pressure drainage, and simultaneously generate comprehensive treatment effects of antibiosis and promotion of tissue healing, thereby improving the treatment effect on chronic and difficult-to-heal wound surfaces such as diabetic ulcer and the like.
Description
Technical field
The invention belongs to field of medical products, relate to a kind of wound-surface plaster of treating wound surface, relate in particular to a kind of metal ion antibacterial and be used for having concurrently of closed negative pressure treatment wound surface antibiotic with wound-surface plaster that promotes the tissue repair function and preparation method thereof.
Background technology
(chitosan, CS) be is raw material with the chitin to chitosan, water-soluble poly-glucosamine that deacetylate obtains in concentrated base.It derives from natural material fully, draws materials conveniently, and is cheap.Aspect physicochemical property, chitosan has excellent biological compatibility, and is biodegradable to human non-toxic, but also has hemostasis, antibacterial activity and film property, thereby has been widely used in fields such as food, medicine, weaving, printing and dyeing, cosmetics and environmental protection.
The application of chitosan aspect medical science mainly contains: (1) promotes blood coagulation and wound healing.Chitosan has the effect that promotes blood coagulation, can be used as hemorrhage.It also can be used for the Wound filling material, has sterilization, promotes wound healing, absorbs Wound exudate, is difficult for effects such as syneresis.(2) as the sustained-release matrix of medicine.Chitosan can be generated natural metabolite by biological intravital lysozyme degraded, has characteristics nontoxic, that can be absorbed fully by organism, therefore has bigger superiority with it as medicinal slow release agent.(3) be used for artificial tissue and organ.The complex of chitosan and calcium phosphate can be used as the substitute of bone, is used for the repairing of bone and the filler of tooth; The composite of chitosan derivatives and polyester can be used as artificial blood vessel.Abewidra once released a kind of new material of repairing burn, ulcer and skin infection---" artificial skin "; This repair materials has the function of natural skin; Not only can make wound avoid the infection of antibacterial, but also can penetration air and moisture, wound healing promoted.(4) has immunoregulatory activity.Chitosan ability activating complement system mediates its biological effect, improves cytophagous function.Exist the receptor of bacterial polysaccharides on the macrophage surface; And chitosan is as the analog of bacterial polysaccharides; Can stimulate macrophage activation, promote its phagocytic function, strengthen its cooperative effect in other immunne response; Thereby realize the adjusting of body, mediated cell immunne response and HI to T cell, NK cell and B cell.(5) other medical usage: chitosan gel rubber can be used as the carrier of tooth antibiotics, has hemostasis, antiinflammatory and conglutinant function; Can reduce the cholesterol concentration in serum and the liver, be used for cholesterol-lowering agent; Chitosan can be strengthened the liver function, prevents because the liver that causes of excessive consumption of alcohol is still drank after a night, and has absorption and excretory effect to remaining in intravital heavy metal, toxin, pesticide, chemical pigment; Chitosan can be regulated intravital pH value to alkalescence, improves the utilization rate of insulin, helps preventing and treating diabetes; In addition, it also has the function of endocrine regulation system, impels insulin secretion normal, suppresses blood sugar increasing, blood fat reducing.
As a kind of natural antibacterial agent, chitosan has better antibacterial activity, can suppress the growth and breeding of part antibacterial, fungus and virus.Mechanism comprises: one, the polycation of chitosan is prone to and the electronegative group effect in fungal cell surface, thereby changes pathogen flowability of cell membranes and permeability; Two, disturb duplicating and transcribing of pathogenic microorganism DNA; Three, blocking-up pathogen metabolism.But its antibacterial efficacy is limited, and it is not satisfactory to continue antibacterial effect, thereby has limited its application in anti-biotic material.
Various types of chronic wound treatments are thorny, are still one of clinical difficult problem that needs to be resolved hurrily at present.With the diabetic ulcer is example: along with the arrival of aging society, the sickness rate of diabetic ulcer increases year by year.Ulcer protracted course of disease, and easy concurrent infection involve deep tissue, can cause that far-end of limb is downright bad, and it is all higher with fatality rate to disable.Known oxidation stress damage is one of crucial paathogenic factor of diabetic ulcer.In tissue, accumulate the response to oxidative stress that is caused by hyperglycemia and terminal glycosylation dead end product (AGEs), but coup injury vascular endothelial cell and function thereof cause microcirculation disturbance, make the organization healing ability drop.
Metallothionein (Metal-lothionein MT) is one type of metal-binding protein that extensively is present in low-molecular-weight in the biological cell, is rich in cysteine, the sulfydryl in its molecule very easily with some electrophilicity material effect, particularly can with combined with radical.Recent study finds that MT is potential antioxidant, has the effect of removing interior free yl, anti-oxidation stress, and damage has protective effect to the diabetes tissue.Type 2 diabetes mellitus patient skeletal muscle and MT in serum level all reduce, and kinetic oxidative stress is lacked reaction, and vivo oxidation system of defense hypofunction is described.
(Vacuum-Assisted Closure is an advanced person's a Wound treating technology VAC) to closed negative pressure drainage,, is popularized rapidly in American-European countries subsequently in initiative in 1992 by German doctor Fleischmann.In recent years, increasing domestic hospital has introduced this technology, as the prefered method of the multiple acute and chronic wound surface of treatment.The deficiency that exists at present mainly is: employed negative pressure treatment dressing only contains medical sponge and drainage tube, lacks good wound surface cladding material, thereby on treatment mechanism, can only utilize the mechanical suction effect of negative pressure, acts on comparatively single; Limited to some with complicacy, the refractory wound surface effect of infection and self healing ability difference.
Summary of the invention
In order to solve the above-mentioned technical problem that exists in the background technology; The invention provides a kind of negative pressure drainage that both guaranteed effectively to implement; Produce antibiotic and the Comprehensive Treatment effect that promotes organization healing simultaneously, thereby improve the negative pressure treatment wound-surface plaster and preparation method thereof of metal ion antibacterial of the therapeutic effect of, refractory wound surface chronic for diabetic ulcer etc.
Technical solution of the present invention is: the negative pressure treatment wound-surface plaster that the invention provides a kind of metal ion antibacterial; The vacuum suction pipe that comprises spongy layer and stretch into spongy layer, its special character is: the wound-surface plaster that said containing metal antibacterial is used to treat wound surface also comprises the non-woven fabrics of combining with spongy layer.
Above-mentioned non-woven fabrics is the chitosan non-woven fabrics.
Above-mentioned non-woven fabrics is a hydrophobicity chitosan non-woven fabrics.
Above-mentioned non-woven fabrics is the chitosan non-woven fabrics of hydrophobicity metal ion antibacterial.
Above-mentioned metal ion antibacterial agent is to contain zinc ion antibacterial, copper ions antibacterial or contain the silver-ion antibiotic agent.
Above-mentioned non-woven fabrics is one or more layers; Preferred 5～15 layers.
Above-mentioned spongy layer is a hydrophilic polyurethane sponge.
A kind of method for preparing of negative pressure treatment wound-surface plaster of metal ion antibacterial, its special character is: said method comprising the steps of:
1) the chitosan non-woven fabrics of preparation metal ion antibacterial;
2) preparation polyurethane sponge layer;
3) with prepared chitosan non-woven fabrics and the step 2 that obtains of step 1)) resulting polyurethane sponge stack.
Above-mentioned steps 1) concrete implementation is:
1.1) the chitosan non-woven fabrics of choosing intermediate molecular weight 30000～60000 dalton, deacetylation 50%～70% is raw material;
1.2) method that adopts propylene polymerization is to step 1.1) resulting chitosan non-woven fabrics carries out metal ion antibacterial agent absorption, is prepared into the chitosan non-woven fabrics that contains metal ion antibacterial agent.
Above-mentioned metal ion antibacterial agent is to contain zinc ion antibacterial, copper ions antibacterial or contain the silver-ion antibiotic agent; When the metal antibacterial agent is when containing zinc ion, said step 1.2) adsorbance of zinc ion is 50～150mg/g in; When the metal antibacterial agent is copper ions, said step 1.2) adsorbance of copper ion is 10～60mg/g in; When the metal antibacterial agent is when containing silver ion, said step 1.2) adsorbance of silver ion is 100～180mg/g in.
Advantage of the present invention is:
The present invention adopts the method for the laggard row metal ionic adsorption of propylene polymerization to prepare the chitosan non-woven fabrics of hydrophobicity metal ion antibacterial, and with itself and hydrophilic polyurethane sponge and vacuum suction pipe Combined application, forms novel block negative pressure treatment wound-surface plaster.This wound-surface plaster and preparation method thereof is applicable to chronic, refractory wound surface such as treatment diabetic ulcer.Use this novel wound-surface plaster, can overcome existing negative pressure treatment dressing and not contain wound surface cladding material, the single deficiency of therapeutical effect.Can effectively implement on the basis of negative pressure drainage, bring into play antibiotic with alleviate the damage of histiocyte oxidative stress, promote the Comprehensive Treatment effect of organization healing, thereby raising is to the therapeutic effect of refractory wound surface.Specific as follows:
(1) novel wound-surface plaster has wound surface drain, antibiotic and promote the Comprehensive Treatment effect of organization healing concurrently; (2) the associating antimicrobial effect of wound-surface plaster performance chitosan and metal ion, it is low that has a broad antifungal spectrum, antibacterial efficacy strengthen, are difficult for generation drug resistance, persistent and toxicity; (3) wound-surface plaster continues to discharge Zn
2+Deng metal ion, but induced tissue cellular expression metallothionein alleviates the cellular oxidation stress damage, promotes wound repair; (4) the membranous type wound-surface plaster has certain intensity and pliability, can avoid directly the grow into micropore of sponge material of wound surface adhesion and new granulation tissue; (5) material good biocompatibility, to human non-toxic, harmless, environmentally friendly.
Description of drawings
Fig. 1 is the structural representation of wound-surface plaster provided by the present invention;
Wherein:
1-vacuum suction pipe; The 2-spongy layer; The 3-nonwoven layer.
The specific embodiment
Theoretical basis of the present invention is: the chitosan material good biocompatibility, to human non-toxic property, be applied to wound surface have antibiotic, preserve moisture and multiple function such as hemostasis.And metal ions such as zinc, copper, silver belong to the inorganic metal antibacterial, and has a broad antifungal spectrum all has good antibacterial performance to escherichia coli, bacillus pyocyaneus and staphylococcus aureus etc.; Safe, toxicity is little, to skin mucosa nonirritant, teratogenesis, not carcinogenic not; Drug resistance is little, and its unique sterilization mechanism makes antibacterial be difficult for producing drug resistance.Metal ion antibacterial agent with after the chitosan non-woven fabrics combines, is realized the associating of antibacterial mechanisms and the lasting release of metal ion, can keep the effective antibiotic concentration of wound surface, strengthened the antibacterial activity of wound-surface plaster.
In addition, zinc, copper are the trace element of needed by human, also are under the physiological condition and the bonded major metal element of metallothionein (MT), can the induced tissue organ in the genetic transcription of MT-I and MT-II, thereby increase the expression of MT.Contain the chitosan of zinc ion or copper ion can be on wound surface slowly, lasting zinc ion releasing or copper ion, thereby induced tissue cell MT expresses and increases, the effect of free radical, antioxidant stress injury is removed in performance, the protective tissue cell promotes wound repair.
Referring to Fig. 1; The invention provides the wound-surface plaster that a kind of metal ion antibacterial is used for closed negative pressure treatment wound surface; This wound-surface plaster is combined to form by the chitosan non-woven fabrics of hydrophobicity metal ion antibacterial 3 and hydrophilic polyurethane sponge 2 and the vacuum suction pipe 1 that stretches into spongy layer; Become realize eventually transudate absorb, antibiotic and promote the negative pressure treatment wound-surface plaster of tissue repair, the metal antibacterial agent can be zinc ion, copper ion or silver ion.
If contain the chitosan of metal ion antibacterial agent is the chitosan that contains zinc ion; Provide technical scheme to specify as follows to the present invention: hydrophobicity contains cadmia polysaccharide non-woven fabrics, and adopting the chitosan non-woven fabrics of intermediate molecular weight (30000～60000), deacetylation 50%～70% is raw material; Employing water is reaction medium, and 5% sodium peroxydisulfate is a reaction initiator, and 8% ferrous sulfate is a polymerization inhibitor, carries out glycerol polymerization behind the adding acrylic acid down at 40 ℃, and controlling reaction time made aggregate rate between 100%～300% between 1～1.5 hour; After polymerization, polymerizate is placed on the absorption of carrying out zinc in 1.5% solution of zinc sulfate through the water depth washing, make the zinc adsorbance reach 50～150mg/g.
Hydrophobicity contains cadmia polysaccharide non-woven fabrics and constitutes by 5～15 layers, and its thickness is about about 3～10mm.In use, owing to have ion exchange process between the contained zinc ion of sodium ion, potassium ion and dressing in blood and the wound exudate, the zinc burst size remains on 0.8～1.7 μ mol/cm in the time of can guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 12～18mm, and porosity is 50%～80%.
Embodiment 1:
Hydrophobicity contains cadmia polysaccharide non-woven fabrics, and adopting the chitosan non-woven fabrics of intermediate molecular weight (60000), deacetylation 50% is raw material, carries out the absorption of zinc ion behind the employing propylene polymerization (aggregate rate 300%), makes the zinc adsorbance reach 150mg/g; Hydrophobicity contains cadmia polysaccharide non-woven fabrics and constitutes by 5 layers, and its thickness is about about 3mm, and the zinc burst size remains on 1.7 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 12mm, and porosity is 50%.
Embodiment 2:
Hydrophobicity contains cadmia polysaccharide non-woven fabrics, and adopting the chitosan non-woven fabrics of intermediate molecular weight (45000), deacetylation 60% is raw material, carries out the absorption of zinc ion behind the employing propylene polymerization (aggregate rate 200%), makes the zinc adsorbance reach 100mg/g; Hydrophobicity contains cadmia polysaccharide non-woven fabrics and constitutes by 10 layers, and its thickness is about about 7mm, and the zinc burst size remains on 1.2 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 15mm, and porosity is 60%.
Embodiment 3:
Hydrophobicity contains cadmia polysaccharide non-woven fabrics, and adopting the chitosan non-woven fabrics of intermediate molecular weight (30000), deacetylation 70% is raw material, carries out the absorption of zinc ion behind the employing propylene polymerization (aggregate rate 100%), makes the zinc adsorbance reach 50mg/g; Hydrophobicity contains cadmia polysaccharide non-woven fabrics and constitutes by 15 layers, and its thickness is about about 10mm, and the zinc burst size remains on 0.8 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 18mm, and porosity is 80%.
If contain the chitosan of metal ion antibacterial agent is the chitosan that contains copper ion; Provide technical scheme to specify as follows to the present invention: hydrophobicity cupric chitosan non-woven fabrics; Adopting the chitosan non-woven fabrics of intermediate molecular weight (30000～60000), deacetylation 50%～70% is raw material; Carry out the absorption of copper ion behind the employing propylene polymerization (aggregate rate 100%～300%), make the copper adsorbance reach 10～60mg/g; Hydrophobicity cupric chitosan non-woven fabrics constitutes by 5～15 layers, and its thickness is about about 3～10mm, and the copper burst size remains on 0.03～0.08 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 12～18mm, and porosity is 50%～80%.
Embodiment 1:
Adopting the chitosan non-woven fabrics of intermediate molecular weight (45000), deacetylation 60% is raw material, carries out the absorption of copper ion behind the employing propylene polymerization (aggregate rate 150%), makes the copper adsorbance reach 45mg/g; Hydrophobicity cupric chitosan non-woven fabrics constitutes by 10 layers, and its thickness is about about 7mm, and the copper burst size remains on 0.05 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 15mm, and porosity is 60%.
Embodiment 2:
Adopting the chitosan non-woven fabrics of intermediate molecular weight (30000), deacetylation 70% is raw material, carries out the absorption of copper ion behind the employing propylene polymerization (aggregate rate 100%), makes the copper adsorbance reach 30mg/g; Hydrophobicity cupric chitosan non-woven fabrics constitutes by 15 layers, and its thickness is about about 10mm, and the copper burst size remains on 0.03 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 18mm, and porosity is 80%.
Embodiment 3:
Adopting the chitosan non-woven fabrics of intermediate molecular weight (60000), deacetylation 50% is raw material, carries out the absorption of copper ion behind the employing propylene polymerization (aggregate rate 300%), makes the copper adsorbance reach 60mg/g; Hydrophobicity cupric chitosan non-woven fabrics constitutes by 5 layers, and its thickness is about about 3mm, and the copper burst size remains on 0.08 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 12mm, and porosity is 50%.
If contain the chitosan of metal ion antibacterial agent is the chitosan that contains silver ion; Provide technical scheme to specify as follows to the present invention: hydrophobicity argentiferous chitosan non-woven fabrics; Adopting the chitosan non-woven fabrics of intermediate molecular weight (30000～60000), deacetylation 50%～70% is raw material; Carry out the absorption of silver ion behind the employing propylene polymerization (aggregate rate 100%～300%), make silver adsorption reach 100～180mg/g; Hydrophobicity argentiferous chitosan non-woven fabrics constitutes by 5～15 layers, and its thickness is about about 3～10mm, and the silver burst size remains on 1.2～1.8 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 12～18mm, and porosity is 50%～80%.
Embodiment 1:
Hydrophobicity argentiferous chitosan non-woven fabrics, adopting the chitosan non-woven fabrics of intermediate molecular weight (60000), deacetylation 50% is raw material, carries out the absorption of silver ion behind the employing propylene polymerization (aggregate rate 300%), makes silver adsorption reach 180mg/g; Hydrophobicity argentiferous chitosan non-woven fabrics constitutes by 5 layers, and its thickness is about about 3mm, and the silver burst size remains on 1.8 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 12mm, and porosity is 50%.
Embodiment 2:
Hydrophobicity argentiferous chitosan non-woven fabrics, adopting the chitosan non-woven fabrics of intermediate molecular weight (45000), deacetylation 60% is raw material, carries out the absorption of silver ion behind the employing propylene polymerization (aggregate rate 200%), makes silver adsorption reach 140mg/g; Hydrophobicity argentiferous chitosan non-woven fabrics constitutes by 10 layers, and its thickness is about about 7mm, and the silver burst size remains on 1.5 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 15mm, and porosity is 60%.
Embodiment 3:
Hydrophobicity argentiferous chitosan non-woven fabrics, adopting the chitosan non-woven fabrics of intermediate molecular weight (30000), deacetylation 70% is raw material, carries out the absorption of silver ion behind the employing propylene polymerization (aggregate rate 100%), makes silver adsorption reach 100mg/g; Hydrophobicity contains cadmia polysaccharide non-woven fabrics and constitutes by 15 layers, and its thickness is about about 10mm, and the silver burst size remains on 1.2 μ mol/cm when guaranteeing to use
2Hydrophilic polyurethane is used to absorb the adsorbed wound fluid of chitosan non-woven fabrics, and its thickness is 18mm, and porosity is 80%.
The zoopery result shows: rabbit back diameter 5cm holostrome skin injury wound surface, and after common negative pressure (not containing novel wound-surface plaster) treatment, The average healing is 17.86 days; After adopting the novel wound-surface plaster treatment that contains zinc ion, copper ion and silver ion respectively, wound healing time was followed successively by 14.72 days, 15.49 days and 15.35 days, and all more common negative pressure treatment group significantly shortens.Explain that novel wound-surface plaster can effectively promote wound healing, shorten healing time.
Claims (10)
1. the negative pressure treatment wound-surface plaster of a metal ion antibacterial, the vacuum suction pipe that comprises spongy layer and stretch into spongy layer is characterized in that: the negative pressure treatment wound-surface plaster of said metal ion antibacterial also comprises the non-woven fabrics of combining with spongy layer.
2. the negative pressure treatment wound-surface plaster of metal ion antibacterial according to claim 1 is characterized in that: said non-woven fabrics is the chitosan non-woven fabrics.
3. the negative pressure treatment wound-surface plaster of metal ion antibacterial according to claim 2 is characterized in that: said non-woven fabrics is a hydrophobicity chitosan non-woven fabrics.
4. the negative pressure treatment wound-surface plaster of metal ion antibacterial according to claim 3 is characterized in that: said non-woven fabrics is the chitosan non-woven fabrics of hydrophobicity metal ion antibacterial.
5. the negative pressure treatment wound-surface plaster of metal ion antibacterial according to claim 4 is characterized in that: said metal ion antibacterial is to contain zinc ion antibacterial, copper ions antibacterial or contain the silver-ion antibiotic agent.
6. according to the negative pressure treatment wound-surface plaster of claim 1 or 2 or 3 or 4 or 5 described metal ion antibacterial, it is characterized in that: said non-woven fabrics is one or more layers; Preferred 5～15 layers.
7. the negative pressure treatment wound-surface plaster of metal ion antibacterial according to claim 6 is characterized in that: said spongy layer is a hydrophilic polyurethane sponge.
8. the method for preparing of the negative pressure treatment wound-surface plaster of a metal ion antibacterial is characterized in that: said method comprising the steps of:
1) the chitosan non-woven fabrics of preparation metal ion antibacterial;
2) preparation polyurethane sponge layer;
3) with prepared chitosan non-woven fabrics and the step 2 that obtains of step 1)) resulting polyurethane sponge stack.
9. the method for preparing of the negative pressure treatment wound-surface plaster of metal ion antibacterial according to claim 8 is characterized in that: the concrete implementation of said step 1) is:
1.1) the chitosan non-woven fabrics of choosing intermediate molecular weight 30000 dalton～60000 dalton, deacetylation 50%～70% is raw material;
1.2) method of utilizing propylene polymerization is to step 1.1) resulting chitosan non-woven fabrics carries out metal ion antibacterial agent absorption, is prepared into the chitosan non-woven fabrics that contains metal ion antibacterial agent.
10. the method for preparing of the negative pressure treatment wound-surface plaster of metal ion antibacterial according to claim 9 is characterized in that: said metal ion antibacterial agent is to contain zinc ion antibacterial, copper ions antibacterial or contain the silver-ion antibiotic agent; When the metal antibacterial agent is when containing zinc ion, said step 1.2) adsorbance of zinc ion is 50～150mg/g in; When the metal antibacterial agent is copper ions, said step 1.2) adsorbance of copper ion is 10～60mg/g in; When the metal antibacterial agent is when containing silver ion, said step 1.2) adsorbance of silver ion is 100～180mg/g in.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110393626XA CN102430146A (en) | 2011-12-01 | 2011-12-01 | Negative pressure treatment wound surface patch containing metal ion antibacterial agent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110393626XA CN102430146A (en) | 2011-12-01 | 2011-12-01 | Negative pressure treatment wound surface patch containing metal ion antibacterial agent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102430146A true CN102430146A (en) | 2012-05-02 |
Family
ID=45978729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110393626XA Pending CN102430146A (en) | 2011-12-01 | 2011-12-01 | Negative pressure treatment wound surface patch containing metal ion antibacterial agent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102430146A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055448A (en) * | 2015-05-25 | 2015-11-18 | 中国人民解放军第三军医大学第一附属医院 | Uses of copper ion preparation in preparation of drug or dressing for promoting skin keratinocyte to proliferate |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060016417A1 (en) * | 2004-07-26 | 2006-01-26 | Tang-Wei Kuo | NOx emission control for a controlled auto-ignition four-stroke internal combustion engine |
| CN200977228Y (en) * | 2006-12-15 | 2007-11-21 | 中国人民解放军第四军医大学 | Closed negative pressure wound surface dressings |
| CN101985049A (en) * | 2010-12-03 | 2011-03-16 | 长沙邦创生物科技有限公司 | Chitosan bandage |
| CN102038575A (en) * | 2010-12-06 | 2011-05-04 | 陈德华 | Wound filling dressing for closed negative pressure drainage of surgical wound as well as preparation method |
| CN202505597U (en) * | 2011-12-01 | 2012-10-31 | 中国人民解放军第四军医大学 | Negative pressure therapy wound paste containing metal ion germicide |
-
2011
- 2011-12-01 CN CN201110393626XA patent/CN102430146A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060016417A1 (en) * | 2004-07-26 | 2006-01-26 | Tang-Wei Kuo | NOx emission control for a controlled auto-ignition four-stroke internal combustion engine |
| CN200977228Y (en) * | 2006-12-15 | 2007-11-21 | 中国人民解放军第四军医大学 | Closed negative pressure wound surface dressings |
| CN101985049A (en) * | 2010-12-03 | 2011-03-16 | 长沙邦创生物科技有限公司 | Chitosan bandage |
| CN102038575A (en) * | 2010-12-06 | 2011-05-04 | 陈德华 | Wound filling dressing for closed negative pressure drainage of surgical wound as well as preparation method |
| CN202505597U (en) * | 2011-12-01 | 2012-10-31 | 中国人民解放军第四军医大学 | Negative pressure therapy wound paste containing metal ion germicide |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055448A (en) * | 2015-05-25 | 2015-11-18 | 中国人民解放军第三军医大学第一附属医院 | Uses of copper ion preparation in preparation of drug or dressing for promoting skin keratinocyte to proliferate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mirhaj et al. | An overview on the recent advances in the treatment of infected wounds: Antibacterial wound dressings | |
| CN103041438B (en) | Moist antibacterial hydrogel dressing for curing diabetic foot ulcer | |
| AU2008205695B2 (en) | Wound dressing with a bacterial adsorbing composition and moisture holding system | |
| KR101377569B1 (en) | Antimicrobial Wound Dressing and Preparing Method of the Same | |
| CN103747814B (en) | Decompression treatment and debridement system and method | |
| CN101313915B (en) | Application of hyaluronic acid and its salt, crosslinked hyaluronic acid and its salt in preparing medicament for treating or preventing sea-soaking injury | |
| JP2022523780A (en) | Antibacterial dressings, dressing components, and methods | |
| CN105012993A (en) | Medical and antibacterial cationic biogel dressing and preparation method thereof | |
| CN102335452A (en) | Formula of functional dressing and preparation method thereof | |
| CN104257602A (en) | Lanthanum rare-earth coordinated chitosan quaternary ammonium salt gynecological gel for external use and preparation method thereof | |
| CN104307030A (en) | Method for preparing quaternary ammonium salt chitosan medical hemostatic dressings through low-temperature plasma catalysis | |
| CN109331215A (en) | A kind of medical antibacterial sponge and preparation method thereof | |
| CN104971377A (en) | Liquid wound glue and preparation method | |
| CN1838970A (en) | Antioxidant wound dressing materials | |
| RU2194535C2 (en) | Preparation for treating the wounds | |
| Zhao et al. | Research advances in hydrogel-based wound dressings for diabetic foot ulcer treatment: a review | |
| CN111407919B (en) | Chitosan quaternary ammonium salt sterilization gauze and preparation method thereof | |
| Fletes-Vargas et al. | Natural hydrogels as wound dressing for skin wound-healing applications | |
| CN202505597U (en) | Negative pressure therapy wound paste containing metal ion germicide | |
| CZ302380B6 (en) | Dry substance of hydrogel to cover wounds and process for preparing thereof | |
| CN101856322B (en) | Sulfadiazine silver controlled-release gel and preparation method thereof | |
| CN102430146A (en) | Negative pressure treatment wound surface patch containing metal ion antibacterial agent and preparation method thereof | |
| CN109432483B (en) | Medical dressing for accelerating wound healing and preparation method and application thereof | |
| KR20190098269A (en) | Preservative compositions comprising unityol and dimethylsulfoxide, uses of the compositions and methods of treating wounds using the same | |
| CN201337582Y (en) | Chitosan bactericidal dressing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120502 |